Orestis Nikolidakis

Orestis Nikolidakis

Auto-generated profile, based on publicly available information

Orestis Nikolidakis

Department of Neurobiology Care Sciences and Society, Division of Neurogeriatrics, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2024 in Science Advances
Verified
Journal Article
Open access
MLMaría Latorre-Leal
María Latorre-Leal
PRPatricia Rodriguez-Rodriguez
Patricia Rodriguez-Rodriguez
LFLuca Franchini
Luca Franchini
ONOrestis Nikolidakis
Orestis Nikolidakis
MDMakrina Daniilidou
Makrina Daniilidou
SMSilvia Maioli
Silvia Maioli
The brain-specific enzyme CYP46A1 controls cholesterol turnover by converting cholesterol into 24 S -hydroxycholesterol (24OH). Dysregulation of brain cholesterol turnover and reduced CYP46A1 levels are observed in Alzheimer’s disease (AD). In this study, we report that CYP46A1 overexpression in aged female mice leads to enhanced estrogen signaling in the hippocampus and improved cognitive functions. In contrast, age-matched CYP46A1 overexpressing males show anxiety-like behavior, worsened memory, and elevated levels of 5α-dihydrotestosterone in the hippocampus. We report that, in neurons, 24OH contributes to these divergent effects by activating sex hormone signaling, including estrogen receptors. CYP46A1 overexpression in female mice protects from memory impairments induced by ovariectomy while having no effects in gonadectomized males. Last, we measured cerebrospinal fluid levels of 24OH in a clinical cohort of patients with AD and found that 24OH negatively correlates with neurodegeneration markers only in women. We suggest that CYP46A1 activation is a valuable pharmacological target for enhancing estrogen signaling in women at risk of developing neurodegenerative diseases.